Cryptogenic Cirrhosis: Causes, Diagnosis, and Treatment in the MASLD Era

What Is Cryptogenic Cirrhosis?

Cryptogenic cirrhosis is a diagnosis of exclusion. Clinicians reach it only after ruling out hepatitis B, hepatitis C, alcohol-related liver disease, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, Wilson disease, and alpha-1 antitrypsin deficiency. The liver shows advanced fibrosis or nodular regeneration on biopsy or imaging, but none of those established causes can be confirmed.

For decades, the "cryptogenic" label implied a genuine mystery. That framing has largely collapsed. Large autopsy and explant series demonstrate that many patients diagnosed with cryptogenic cirrhosis had obesity, type 2 diabetes, or metabolic syndrome, and that steatosis simply disappears as hepatic fat is replaced by fibrous tissue during advanced disease [1]. The 2023 Delphi consensus renamed nonalcoholic fatty liver disease to metabolic dysfunction-associated steatotic liver disease (MASLD), and nonalcoholic steatohepatitis to metabolic dysfunction-associated steatohepatitis (MASH), specifically to reflect the metabolic substrate driving most cases [2].

Recognizing burned-out MASLD as the culprit in cryptogenic cirrhosis changes management decisions, transplant listing criteria, and post-transplant surveillance protocols in concrete ways.

How Common Is Cryptogenic Cirrhosis and Who Gets It?

The condition is not rare. Cryptogenic cirrhosis accounts for roughly 5 to 30 percent of all cirrhosis diagnoses in Western tertiary hepatology centers, depending on how aggressively other causes are excluded [3]. The wide range reflects differences in workup completeness. Centers that routinely perform genetic testing and extended autoimmune panels reclassify more cases and report lower cryptogenic rates.

The metabolic profile of affected patients is striking. Studies comparing cryptogenic cirrhosis patients with those who have biopsy-confirmed MASH cirrhosis find nearly identical body mass index distributions, rates of type 2 diabetes (approximately 50 percent in both groups), and lipid abnormalities [4]. Women over 50 appear overrepresented, possibly because estrogen loss after menopause accelerates visceral adiposity and hepatic fat accumulation before fibrosis eventually erases the histological footprint.

MASLD itself affects an estimated 32.4 percent of the global adult population based on a 2023 systematic review of approximately 5 million individuals, making it the single largest contributor to chronic liver disease worldwide [5]. Even a small percentage progression rate to MASH cirrhosis produces a large absolute number of patients who may present at the burned-out stage without recognizable steatosis.

Why Steatosis Disappears: The Burned-Out MASH Concept

Fat vanishes from the liver as fibrosis advances. This is not speculative. Matched biopsy data from the NASH Clinical Research Network shows progressive reductions in steatosis grade as fibrosis stage increases from F1 to F4, with many F4 patients showing minimal or absent fat on repeat biopsy [6]. Hepatic stellate cell activation and sinusoidal capillarization disrupt normal lipid uptake and storage. Ongoing protein-calorie wasting in decompensated cirrhosis further depletes adipose reserves.

Inflammation markers follow a similar arc. Lobular inflammation and hepatocyte ballooning, the histological hallmarks of MASH, become less prominent as the disease burns through susceptible hepatocytes and replaces functional parenchyma with scar. A liver biopsy taken at the F4 stage may look entirely non-specific, containing only nodular regeneration and dense fibrosis without a single ballooned cell [7].

This biological reality means that the absence of steatosis on biopsy does not exclude a prior MASH diagnosis. Clinicians who anchor their thinking on current histology will miss the underlying etiology.

Diagnostic Workup: Excluding Other Causes Systematically

A structured exclusion protocol separates true cryptogenic cirrhosis from reclassifiable cases. The American Association for the Study of Liver Diseases (AASLD) 2023 guidance on MASLD specifies that MASLD diagnosis requires at least one of five cardiometabolic risk criteria: BMI above 25 kg/m², waist circumference above sex-specific thresholds, pre-diabetes or type 2 diabetes, hypertension, or dyslipidemia [2].

The minimum exclusion workup for a patient presenting with cirrhosis of unknown cause should include [8]:

• Hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody with reflex RNA testing
• Alcohol use history quantified by validated questionnaire (AUDIT-C) plus carbohydrate-deficient transferrin if history is uncertain
• Antinuclear antibody, anti-smooth muscle antibody, anti-liver-kidney microsomal antibody, serum IgG
• Antimitochondrial antibody with IgM for primary biliary cholangitis
• Serum ferritin, transferrin saturation, and HFE gene mutation analysis for hemochromatosis
• Serum ceruloplasmin and 24-hour urine copper for Wilson disease in patients under 55
• Alpha-1 antitrypsin phenotyping
• Thyroid function (hypothyroidism drives steatosis independently)

Only after all of these return non-diagnostic should the cirrhosis be labeled cryptogenic. In practice, adding metabolic phenotyping, including a glucose tolerance test, fasting insulin, and HOMA-IR, frequently identifies patients whose cirrhosis is best attributed to burned-out MASH even without confirmatory histology [9].

Non-Invasive Fibrosis Assessment: FIB-4, Elastography, and ELF

Biopsy remains the reference standard for fibrosis staging. Its limitations are well documented: sampling variability, procedural risk in coagulopathic patients, and cost. Non-invasive tests have assumed a central clinical role.

FIB-4 score, calculated from age, AST, ALT, and platelet count, is the most validated entry-level tool. The AASLD and European Association for the Study of the Liver (EASL) jointly recommend FIB-4 as the first-line fibrosis triage test, with a score below 1.30 having a negative predictive value exceeding 90 percent for advanced fibrosis in MASLD populations [10]. A score above 2.67 warrants referral to hepatology regardless of steatosis visibility.

Vibration-controlled transient elastography (FibroScan) measures liver stiffness in kilopascals. In MASLD populations, a liver stiffness measurement (LSM) above 15 kPa has approximately 85 percent sensitivity and 90 percent specificity for cirrhosis [11]. The Enhanced Liver Fibrosis (ELF) panel, measuring tissue inhibitor of metalloproteinase-1, hyaluronic acid, and pro-collagen III N-terminal peptide, adds independent predictive value when FIB-4 results fall in the indeterminate 1.30 to 2.67 range [12].

For patients presenting with cryptogenic cirrhosis specifically, combining LSM above 25 kPa with a metabolic phenotype consistent with MASLD provides sufficient evidence to classify the etiology as burned-out MASH for clinical management purposes, even in the absence of current steatosis on imaging or biopsy [13].

Hepatocellular Carcinoma Risk in Cryptogenic and MASLD-Related Cirrhosis

HCC risk is real and substantial. Cirrhotic MASLD carries an annual HCC incidence of 2 to 4 percent, comparable to hepatitis C cirrhosis [14]. The landmark NASH CRN study found that patients with MASH-related cirrhosis developed HCC at a rate of 2.6 percent per year over a median follow-up of 5.6 years [15].

Cryptogenic cirrhosis carries similar or even slightly elevated HCC risk compared with confirmed MASH cirrhosis, possibly because patients go undiagnosed longer and present at a more advanced stage [16]. The AASLD 2023 HCC surveillance guidance states: "All patients with cirrhosis, regardless of etiology, should undergo surveillance with liver ultrasound with or without alpha-fetoprotein (AFP) every 6 months" [17].

AFP alone misses 40 percent of early HCC in MASLD populations. Combining ultrasound with AFP improves sensitivity to approximately 63 percent for very early (BCLC 0) tumors [18]. Abbreviated MRI protocols are being evaluated as higher-sensitivity alternatives in patients with poor ultrasound windows due to obesity, which is common in this population.

The Role of MASLD in the Transplant Setting

Liver transplantation is definitive treatment for decompensated cryptogenic cirrhosis. MASLD is now the fastest-growing indication for transplant listing in the United States, having surpassed hepatitis C in new listings at many centers [19]. Patients listed with cryptogenic cirrhosis who carry metabolic risk factors should be counseled that the underlying MASLD diagnosis may become apparent only at explant pathology.

Post-transplant outcomes are generally good. Five-year patient survival exceeds 70 percent in most series, similar to other non-viral etiologies [20]. The major concern is disease recurrence. MASLD recurs histologically in up to 100 percent of recipients within 5 years when metabolic risk factors are not aggressively managed, and 10 to 25 percent develop MASH on the allograft [21].

Immunosuppression choices influence recurrence. Tacrolimus and corticosteroids worsen insulin resistance and promote weight gain. Mycophenolate mofetil-based regimens with early steroid withdrawal may reduce metabolic burden, though prospective comparative data remain limited [22]. Post-transplant metabolic syndrome should be managed with the same rigor applied to non-transplant patients: structured weight loss, antidiabetic agents chosen for hepatic safety, and statin therapy where indicated.

Pharmacological Treatment: What Works in MASH Fibrosis

Until March 2024, no drug held FDA approval for MASH-related fibrosis. Resmetirom (Rezdiffra, Madrigal Pharmaceuticals) changed that. In the MAESTRO-NASH trial (N=966), resmetirom 100 mg daily for 52 weeks achieved MASH resolution without worsening fibrosis in 25.9 percent of patients versus 14.2 percent on placebo (P<0.001), and a one-stage or greater fibrosis improvement in 25.9 percent versus 14.2 percent [23]. The FDA approved resmetirom on March 14, 2024, for adults with MASH and moderate to advanced hepatic fibrosis (F2 or F3).

Resmetirom is a liver-directed thyroid hormone receptor beta agonist. It does not currently have an approved indication for F4 (cirrhotic) MASH, which is directly relevant to patients with cryptogenic cirrhosis where the metabolic underpinning is suspected. Extension studies and a dedicated compensated cirrhosis cohort are ongoing.

Semaglutide (Ozempic, Wegovy) showed MASH histological improvement in the ESSENCE trial. At 72 weeks, semaglutide 2.4 mg subcutaneously weekly achieved MASH resolution in 62.9 percent of participants versus 34.3 percent on placebo (P<0.001) [24]. Fibrosis improvement reached statistical significance as well. The FDA is currently reviewing semaglutide for a MASH indication. For patients with cryptogenic cirrhosis and concurrent obesity or type 2 diabetes, GLP-1 receptor agonist therapy addresses both the suspected underlying etiology and cardiometabolic comorbidities simultaneously.

Vitamin E (800 IU/day) reduces hepatocyte ballooning in non-diabetic, non-cirrhotic MASH per the PIVENS trial (N=247), but its use in cirrhosis is not supported by controlled data and carries theoretical concerns about hemorrhagic risk in coagulopathic patients [25].

Pioglitazone, an insulin sensitizer, reduces hepatic steatosis and inflammation in MASH but has not been tested in established cirrhosis. Weight gain and fluid retention limit its use in decompensated patients [26].

Metabolic and Lifestyle Interventions: The Evidence Base

Weight loss is dose-dependent in its hepatic effects. The AASLD states explicitly: "Weight loss of at least 5 percent improves steatosis; 7 to 10 percent improves histological MASH activity; greater than 10 percent may improve fibrosis" [27]. In a 52-week randomized trial by Vilar-Gomez et al. (N=293), patients achieving greater than 10 percent weight loss showed fibrosis improvement in 45 percent of cases versus 8 percent in those losing less than 5 percent [28].

Exercise contributes independently of weight loss. Aerobic exercise at 150 minutes per week of moderate intensity reduces hepatic fat content by approximately 20 to 30 percent as measured by MRS even without significant scale changes [29]. Resistance training adds benefit by improving insulin sensitivity and reducing visceral adiposity, which is the depot most tightly correlated with hepatic fat accumulation.

Dietary composition matters beyond total calories. The Mediterranean diet reduces hepatic steatosis and metabolic syndrome markers more than a standard low-fat diet in controlled trials [30]. Fructose restriction, particularly elimination of sugar-sweetened beverages, reduces hepatic de novo lipogenesis and lowers liver enzymes within 8 weeks in overweight adolescents and adults [31].

Alcohol abstinence is non-negotiable. Even moderate alcohol intake accelerates fibrosis progression in MASLD, with daily consumption above 10 grams per day associated with a hazard ratio of 1.4 for advanced fibrosis in the European NAFLD Registry cohort [32].

Monitoring Decompensation and Managing Complications

Patients with cryptogenic cirrhosis require the same complication surveillance protocol applied to any cirrhosis etiology. Upper endoscopy screens for esophageal and gastric varices at diagnosis, with repeat intervals determined by findings and Child-Pugh class per AASLD and BAVENO VII guidelines [33]. Propranolol or carvedilol reduce variceal bleeding risk in patients with medium or large varices or those with high-risk stigmata.

Spontaneous bacterial peritonitis (SBP) prophylaxis with norfloxacin 400 mg daily is indicated for patients with ascitic fluid protein below 1.5 g/dL and either Child-Pugh score above 9 or renal impairment [34]. Hepatic encephalopathy is managed with lactulose titrated to two to three soft stools per day, with rifaximin 550 mg twice daily added for secondary prevention after a first episode [35].

MELD-Na score calculated every 3 to 6 months guides transplant listing urgency. Patients with MELD-Na above 15 generally benefit from transplant evaluation referral before further decompensation [36].

Original Clinical Framework: Reclassifying Cryptogenic Cirrhosis at Presentation

The following five-step approach, developed by the HealthRX hepatology advisory panel, standardizes metabolic reclassification of cryptogenic cirrhosis at initial presentation:

Step 1. Confirm true cryptogenic status. Run the full exclusion panel listed above. Add celiac serology and thyroid function if not already done. Re-classify any case where a cause is identified.

Step 2. Apply MASLD metabolic criteria. Score the patient against the five cardiometabolic criteria from the 2023 Delphi consensus. One criterion met plus unexplained cirrhosis supports probable burned-out MASH.

Step 3. Quantify prior steatosis exposure. Review serial imaging (ultrasound, CT, MRI) going back 10 or more years. Historical steatosis documented before fibrosis advanced is strong supporting evidence.

Step 4. Assess current non-invasive fibrosis markers. Record FIB-4, LSM by elastography, and ELF score. Document trajectory, not just current values.

Step 5. Assign a working etiology and document it. Use "probable burned-out MASH" as the operative diagnosis in clinical notes and transplant paperwork when metabolic criteria are met. This drives appropriate post-transplant monitoring and metabolic therapy.

This framework reduces diagnostic uncertainty and ensures that patients receive MASLD-specific surveillance and treatment planning rather than watchful waiting under an ambiguous label.

Special Populations: Women, Lean MASLD, and Genetic Risk

Cryptogenic cirrhosis in women who have never had obesity deserves particular attention. Lean MASLD, defined as MASLD in patients with BMI below 25 kg/m² in Western populations or below 23 kg/m² in Asian populations, accounts for 10 to 20 percent of all MASLD cases [37]. These patients often have normal or near-normal liver enzymes, making them easy to miss. Insulin resistance and visceral adiposity, assessed by waist-to-hip ratio rather than BMI, remain the relevant metabolic variables.

Genetic variants amplify risk substantially. The PNPLA3 rs738409 G allele increases MASH risk by approximately 3-fold and accelerates fibrosis progression [38]. The TM6SF2 rs58542926 T allele and MBOAT7 rs641738 T allele each contribute independently. Patients with cryptogenic cirrhosis who lack typical metabolic risk factors should be offered PNPLA3 genotyping, as a homozygous GG result substantially supports a MASLD etiology even in lean individuals [39].

HSD17B13 rs72613567 loss-of-function variant is protective: carriers have reduced risk of MASH progression by approximately 17 percent per allele. Its presence in a patient with cryptogenic cirrhosis does not exclude MASLD as the cause but does reduce the probability [40].

Key Numbers Every Clinician Should Know

Fibrosis stage F0 to F1 carries a 0.1 percent annual liver-related mortality rate. That rate climbs to 1.0 percent at F3 and 3.3 percent at F4 based on the NASH CRN natural history cohort [41]. Patients with compensated MASH cirrhosis have a 3 percent annual rate of first decompensation, rising to 20 percent annually after the first decompensation event [42].

MELD-Na score predicts 90-day mortality in cirrhosis with a c-statistic of approximately 0.83 across etiologies, including cryptogenic [43]. Patients listed for liver transplant with MELD-Na above 25 have a 90-day waiting-list mortality above 10 percent without transplant.

In MAESTRO-NASH, patients on resmetirom also showed a 26.6 percent reduction in LDL cholesterol and a 19.4 percent reduction in triglycerides at 52 weeks, reflecting the drug's hepatic lipid metabolism effects beyond fibrosis regression [23].